{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:13:43Z","timestamp":1791591223419,"version":"4.3.4"},"reference-count":62,"publisher":"American Chemical Society (ACS)","issue":"9","license":[{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA253655"],"award-info":[{"award-number":["1R01CA253655"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01?CA198989"],"award-info":[{"award-number":["U01?CA198989"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007234","name":"University of Chicago","doi-asserted-by":"publisher","award":["P30 CA014599"],"award-info":[{"award-number":["P30 CA014599"]}],"id":[{"id":"10.13039\/100007234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["PC170934P2"],"award-info":[{"award-number":["PC170934P2"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ludwig Institute for Metastasis Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,15]]},"abstract":"<jats:title>Conspectus<\/jats:title>\n                  <jats:p>Cancer immunotherapy, particularly checkpoint blockade immunotherapy (CBI), has revolutionized the treatment of some cancers by reactivating the antitumor immunity of hosts with durable response and manageable toxicity. However, many cancer patients with low tumor antigen exposure and immunosuppressive tumor microenvironments do not respond to CBI. A variety of methods have been investigated to reverse immunosuppressive tumor microenvironments and turn \u201ccold\u201d tumors \u201chot\u201d with the goal of extending the therapeutic benefits of CBI to a broader population of cancer patients. Immunostimulatory adjuvant treatments, such as cancer vaccines, photodynamic therapy (PDT), radiotherapy (RT), radiotherapy\u2013radiodynamic therapy (RT-RDT), and chemodynamic therapy (CDT), promote antigen presentation and T cell priming and, when used in combination with CBI, reactivate and sustain systemic antitumor immunity. Cancer vaccines directly provide tumor antigens, while immunoadjuvant therapies such as PDT, RT, RT-RDT, and CDT kill cancer cells in an immunogenic fashion to release tumor antigens in situ. Direct administration of tumor antigens or indirect intratumoral immunoadjuvant therapies as in situ cancer vaccines initiate the immuno-oncology cycle for antitumor immune response.<\/jats:p>\n                  <jats:p>With the rapid growth of cancer nanotechnology in the past two decades, a large number of nanoparticle platforms have been studied, and some nanomedicines have been translated into clinical trials. Nanomedicine provides a promising strategy to enhance the efficacy of immunoadjuvant therapies to potentiate cancer immunotherapy. Among these nanoparticle platforms, nanoscale metal\u2013organic frameworks (nMOFs) have emerged as a unique class of porous hybrid nanomaterials with metal cluster secondary building units and organic linkers. With molecular modularity, structural tunability, intrinsic porosity, tunable stability, and biocompatibility, nMOFs are ideally suited for biomedical applications, particularly cancer treatments.<\/jats:p>\n                  <jats:p>In this Account, we present recent breakthroughs in the design of nMOFs as nanocarriers for cancer vaccine delivery and as nanosensitizers for PDT, CDT, RT, and RT-RDT. The versatility of nMOFs allows them to be fine-tuned to effectively load tumor antigens and immunoadjuvants as cancer vaccines and significantly enhance the local antitumor efficacy of PDT, RT, RT-RDT, and CDT via generation of reactive oxygen species (ROS) for in situ cancer vaccination. These nMOF-based treatments are further combined with cancer immunotherapies to elicit systemic antitumor immunity. We discuss novel strategies to enhance light tissue penetration and overcome tumor hypoxia in PDT, to increase energy deposition and ROS diffusion in RT, to combine the advantages of PDT and RT to enable RT-RDT, and to trigger CDT by hijacking aberrant metabolic processes in tumors. Loading nMOFs with small-molecule drugs such as an indoleamine 2,3-dioxygenase inhibitor, the toll-like receptor agonist imiquimod, and biomacromolecules such as CpG oligodeoxynucleotides and anti-CD47 antibody synergizes with nMOF-based radical therapies to enhance their immunotherapeutic effects. Further combination with immune checkpoint inhibitors activates systemic antitumor immune responses and elicits abscopal effects. With structural and compositional tunability, nMOFs are poised to provide a new clinically deployable nanotechnology platform to promote immunostimulatory tumor microenvironments by delivering cancer vaccines, mediating PDT, enhancing RT, enabling RT-RDT, and catalyzing CDT and potentiate cancer immunotherapy.<\/jats:p>","DOI":"10.1021\/acs.accounts.0c00313","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T10:34:19Z","timestamp":1597746859000},"page":"1739-1748","source":"Crossref","is-referenced-by-count":215,"title":["Nanoscale Metal\u2013Organic Frameworks for Cancer\nImmunotherapy"],"prefix":"10.1021","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8152-6746","authenticated-orcid":true,"given":"Kaiyuan","family":"Ni","sequence":"first","affiliation":[{"name":"The University of Chicago , , , ,","place":["Chicago, Illinois, United States, 60637"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taokun","family":"Luo","sequence":"additional","affiliation":[{"name":"The University of Chicago , , , ,","place":["Chicago, Illinois, United States, 60637"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey T.","family":"Nash","sequence":"additional","affiliation":[{"name":"The University of Chicago , , , ,","place":["Chicago, Illinois, United States, 60637"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7035-7759","authenticated-orcid":true,"given":"Wenbin","family":"Lin","sequence":"additional","affiliation":[{"name":"The University of Chicago , , , ,","place":["Chicago, Illinois, United States, 60637"]},{"name":"The University of Chicago , , , ,","place":["Chicago, Illinois, United States, 60637"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2020,8,18]]},"reference":[{"issue":"38","key":"2026081806104976000_cit1","doi-asserted-by":"publisher","first-page":"12502","DOI":"10.1021\/jacs.6b06663","article-title":"Chlorin-based nanoscale metal\u2013organic framework systemically\nrejects colorectal cancers via synergistic photodynamic therapy and\ncheckpoint blockade immunotherapy","volume":"138","author":"Lu","year":"2016","journal-title":"J. Am. Chem.\nSoc."},{"issue":"1","key":"2026081806104976000_cit2","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1038\/s41467-018-04703-w","article-title":"Nanoscale metal\u2013organic\nframeworks enhance radiotherapy to potentiate checkpoint blockade\nimmunotherapy","volume":"9","author":"Ni","year":"2018","journal-title":"Nat. Commun."},{"issue":"8","key":"2026081806104976000_cit3","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41551-018-0203-4","article-title":"Low-dose X-ray radiotherapy\u2013radiodynamic\ntherapy via nanoscale metal\u2013organic frameworks enhances checkpoint\nblockade immunotherapy","volume":"2","author":"Lu","year":"2018","journal-title":"Nat. Biomed. Eng."},{"issue":"7","key":"2026081806104976000_cit4","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.chempr.2019.05.013","article-title":"Nanoscale metal\u2013organic\nframework mediates radical therapy\nto enhance cancer immunotherapy","volume":"5","author":"Ni","year":"2019","journal-title":"Chem."},{"issue":"5","key":"2026081806104976000_cit5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3322\/caac.21565","article-title":"Cancer\ntreatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019","journal-title":"Ca-Cancer J. Clin."},{"issue":"7378","key":"2026081806104976000_cit6","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"issue":"1","key":"2026081806104976000_cit7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology:\nthe cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"4","key":"2026081806104976000_cit8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrc3246","article-title":"The determinants\nof tumour immunogenicity","volume":"12","author":"Blankenstein","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"2026081806104976000_cit9","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer\nimmunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"issue":"8","key":"2026081806104976000_cit10","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1158\/1078-0432.CCR-04-1469","article-title":"Clinical significance\nof programmed death-1 ligand-1 and programmed\ndeath-1 ligand-2 expression in human esophageal cancer","volume":"11","author":"Ohigashi","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"2026081806104976000_cit11","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-03-3259","article-title":"PD-L1\/B7H-1\ninhibits the effector\nphase of tumor rejection by T cell receptor (TCR) transgenic CD8+\nT cells","volume":"64","author":"Blank","year":"2004","journal-title":"Cancer Res."},{"issue":"10","key":"2026081806104976000_cit12","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/nri2163","article-title":"IDO and regulatory\nT cells: a role for reverse signalling\nand non-canonical NF-\u03baB activation","volume":"7","author":"Puccetti","year":"2007","journal-title":"Nat.\nRev. Immunol."},{"issue":"5","key":"2026081806104976000_cit13","doi-asserted-by":"publisher","first-page":"e20192282","DOI":"10.1084\/jem.20192282","article-title":"Intratumoral accumulation of gut microbiota facilitates CD47-based\nimmunotherapy via STING signaling","volume":"217","author":"Shi","year":"2020","journal-title":"J. Exp. Med."},{"issue":"6230","key":"2026081806104976000_cit14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune\ncheckpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"issue":"7","key":"2026081806104976000_cit15","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nrmicro1681","article-title":"The perfect\nmix: recent progress in adjuvant research","volume":"5","author":"Guy","year":"2007","journal-title":"Nat.\nRev. Microbiol."},{"issue":"17","key":"2026081806104976000_cit16","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line\ntreatment in stage IIIB\/IV non\u2013small-cell lung cancer: results\nfrom a randomized, double-blind, multicenter phase II study","volume":"30","author":"Lynch","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"2026081806104976000_cit17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab\nplus nab-paclitaxel as first-line treatment for unresectable, locally\nadvanced or metastatic triple-negative breast cancer (IMpassion130):\nupdated efficacy results from a randomised, double-blind, placebo-controlled,\nphase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol."},{"issue":"1","key":"2026081806104976000_cit18","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.semradonc.2014.07.003","article-title":"Current clinical trials\ntesting combinations of immunotherapy and radiation","volume":"25","author":"Crittenden","year":"2015","journal-title":"Semin. Radiat. Oncol."},{"issue":"6","key":"2026081806104976000_cit19","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41578-019-0108-1","article-title":"Cancer\nnanomedicine for combination cancer immunotherapy","volume":"4","author":"Nam","year":"2019","journal-title":"Nat. Rev. Mater."},{"issue":"6149","key":"2026081806104976000_cit20","doi-asserted-by":"publisher","first-page":"1230444","DOI":"10.1126\/science.1230444","article-title":"The Chemistry and\nApplications of Metal-Organic Frameworks","volume":"341","author":"Furukawa","year":"2013","journal-title":"Science"},{"issue":"10","key":"2026081806104976000_cit21","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1021\/ar200028a","article-title":"Nanoscale metal\u2013organic\nframeworks for biomedical imaging and drug delivery","volume":"44","author":"Della\nRocca","year":"2011","journal-title":"Acc. Chem. Res."},{"issue":"28","key":"2026081806104976000_cit22","doi-asserted-by":"publisher","first-page":"9024","DOI":"10.1021\/ja0627444","article-title":"Nanoscale\nmetal\u2013organic frameworks as potential multimodal contrast enhancing\nagents","volume":"128","author":"Rieter","year":"2006","journal-title":"J. Am. Chem. Soc."},{"issue":"44","key":"2026081806104976000_cit23","doi-asserted-by":"publisher","first-page":"14358","DOI":"10.1021\/ja803777x","article-title":"Manganese-based\nnanoscale metal\u2013organic\nframeworks for magnetic resonance imaging","volume":"130","author":"Taylor","year":"2008","journal-title":"J.\nAm. Chem. Soc."},{"issue":"40","key":"2026081806104976000_cit24","doi-asserted-by":"publisher","first-page":"14261","DOI":"10.1021\/ja906198y","article-title":"Postsynthetic\nmodifications of iron-carboxylate nanoscale metal\u2013organic frameworks\nfor imaging and drug delivery","volume":"131","author":"Taylor-Pashow","year":"2009","journal-title":"J. Am. Chem.\nSoc."},{"issue":"6","key":"2026081806104976000_cit25","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1021\/acscentsci.0c00397","article-title":"Nanoscale Metal\u2013Organic Frameworks Generate\nReactive Oxygen Species for Cancer Therapy","volume":"6","author":"Ni","year":"2020","journal-title":"ACS Cent. Sci."},{"issue":"12","key":"2026081806104976000_cit26","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.tcb.2003.10.004","article-title":"Cues for apoptotic cell engulfment:\neat-me, don\u2019t\neat-me and come-get-me signals","volume":"13","author":"Grimsley","year":"2003","journal-title":"Trends Cell\nBiol."},{"issue":"1","key":"2026081806104976000_cit27","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1146\/annurev.immunol.021908.132603","article-title":"HMGB1 and\nRAGE in Inflammation and Cancer","volume":"28","author":"Sims","year":"2010","journal-title":"Annu. Rev.\nImmunol."},{"issue":"12","key":"2026081806104976000_cit28","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/nrmicro2668","article-title":"The development\nof vaccines: how the past led to the\nfuture","volume":"9","author":"Plotkin","year":"2011","journal-title":"Nat. Rev. Microbiol."},{"issue":"17","key":"2026081806104976000_cit29","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against\nanal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"6449","key":"2026081806104976000_cit30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1126\/science.aav8692","article-title":"Enhanced CAR\u2013T cell activity against solid tumors\nby vaccine boosting through the chimeric receptor","volume":"365","author":"Ma","year":"2019","journal-title":"Science"},{"issue":"11","key":"2026081806104976000_cit31","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/nbt.3398","article-title":"Big thinking for\nadjuvants","volume":"33","author":"Dane","year":"2015","journal-title":"Nat.\nBiotechnol."},{"issue":"3","key":"2026081806104976000_cit32","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nri.2017.131","article-title":"Towards\npersonalized, tumour-specific,\ntherapeutic vaccines for cancer","volume":"18","author":"Hu","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"2026081806104976000_cit33","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/nrd2224","article-title":"More than one reason to rethink the\nuse of peptides in vaccine design","volume":"6","author":"Purcell","year":"2007","journal-title":"Nat. Rev.\nDrug Discovery"},{"issue":"35","key":"2026081806104976000_cit34","doi-asserted-by":"publisher","first-page":"6454","DOI":"10.1002\/adfm.201600650","article-title":"Metal-organic-framework-based\nvaccine platforms for\nenhanced systemic immune and memory response","volume":"26","author":"Zhang","year":"2016","journal-title":"Adv. Funct. Mater."},{"key":"2026081806104976000_cit35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jconrel.2019.02.035","article-title":"An aluminum adjuvant-integrated\nnano-MOF as antigen delivery system\nto induce strong humoral and cellular immune responses","volume":"300","author":"Zhong","year":"2019","journal-title":"J. Controlled Release"},{"issue":"6382","key":"2026081806104976000_cit36","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer\nimmunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"issue":"4","key":"2026081806104976000_cit37","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nmat4822","article-title":"Designer vaccine nanodiscs for personalized\ncancer\nimmunotherapy","volume":"16","author":"Kuai","year":"2017","journal-title":"Nat. Mater."},{"issue":"10","key":"2026081806104976000_cit38","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/s41551-019-0436-x","article-title":"Engineering patient-specific\ncancer immunotherapies","volume":"3","author":"Scheetz","year":"2019","journal-title":"Nat. Biomed. Eng."},{"issue":"9","key":"2026081806104976000_cit39","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41563-018-0147-9","article-title":"Biomaterial-assisted targeted modulation of immune\ncells in cancer treatment","volume":"17","author":"Wang","year":"2018","journal-title":"Nat. Mater."},{"issue":"3","key":"2026081806104976000_cit40","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1172\/JCI33583","article-title":"Plasmacytoid dendritic cells induce NK cell\u2013dependent, tumor\nantigen\u2013specific T cell cross-priming and tumor regression\nin mice","volume":"118","author":"Liu","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"1","key":"2026081806104976000_cit41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-019-0272-7","article-title":"Oncolysis without viruses\ue5f8inducing\nsystemic anticancer immune responses with local therapies","volume":"17","author":"Kepp","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"2026081806104976000_cit42","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nrc1071","article-title":"Photodynamic\ntherapy for cancer","volume":"3","author":"Dolmans","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"48","key":"2026081806104976000_cit43","doi-asserted-by":"publisher","first-page":"16712","DOI":"10.1021\/ja508679h","article-title":"Nanoscale\nMetal\u2013Organic Framework for Highly\nEffective Photodynamic Therapy of Resistant Head and Neck Cancer","volume":"136","author":"Lu","year":"2014","journal-title":"J. Am. Chem. Soc."},{"issue":"24","key":"2026081806104976000_cit44","doi-asserted-by":"publisher","first-page":"7600","DOI":"10.1021\/jacs.5b04069","article-title":"A chlorin-based\nnanoscale metal\u2013organic framework\nfor photodynamic therapy of colon cancers","volume":"137","author":"Lu","year":"2015","journal-title":"J.\nAm. Chem. Soc."},{"issue":"16","key":"2026081806104976000_cit45","doi-asserted-by":"publisher","first-page":"7334","DOI":"10.1021\/jacs.0c02129","article-title":"Nanoscale\nMetal\u2013Organic Frameworks\nStabilize Bacteriochlorins for Type I and Type II Photodynamic Therapy","volume":"142","author":"Luo","year":"2020","journal-title":"J. Am. Chem. Soc."},{"issue":"10","key":"2026081806104976000_cit46","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1021\/jacs.8b13804","article-title":"Titanium-Based Nanoscale Metal\u2013Organic Framework\nfor Type I Photodynamic Therapy","volume":"141","author":"Lan","year":"2019","journal-title":"J. Am. Chem.\nSoc."},{"issue":"7","key":"2026081806104976000_cit47","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1002\/anie.201911508","article-title":"Nd3+-Sensitized Upconversion Metal\u2013Organic\nFrameworks for Mitochondria-Targeted Amplified Photodynamic Therapy","volume":"59","author":"Liu","year":"2020","journal-title":"Angew. Chem., Int. Ed."},{"issue":"39","key":"2026081806104976000_cit48","doi-asserted-by":"publisher","first-page":"13804","DOI":"10.1021\/jacs.7b07302","article-title":"Heterodimers\nmade of upconversion nanoparticles and metal\u2013organic frameworks","volume":"139","author":"Li","year":"2017","journal-title":"J. Am. Chem. Soc."},{"issue":"7","key":"2026081806104976000_cit49","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrc1894","article-title":"Photodynamic\ntherapy and anti-tumour\nimmunity","volume":"6","author":"Castano","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"2026081806104976000_cit50","doi-asserted-by":"publisher","first-page":"4630","DOI":"10.1021\/acsnano.8b01186","article-title":"\u03c0-extended\nbenzoporphyrin-based\nmetal\u2013organic framework for inhibition of tumor metastasis","volume":"12","author":"Zeng","year":"2018","journal-title":"ACS Nano"},{"issue":"17","key":"2026081806104976000_cit51","doi-asserted-by":"publisher","first-page":"5670","DOI":"10.1021\/jacs.8b01072","article-title":"Nanoscale\nmetal\u2013organic framework overcomes hypoxia for photodynamic\ntherapy primed cancer immunotherapy","volume":"140","author":"Lan","year":"2018","journal-title":"J. Am.\nChem. Soc."},{"issue":"3","key":"2026081806104976000_cit52","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1002\/ange.201911429","article-title":"A Nanoscale Metal\u2013Organic\nFramework to Mediate Photodynamic Therapy and Deliver CpG Oligodeoxynucleotides\nto Enhance Antigen Presentation and Cancer Immunotherapy","volume":"132","author":"Ni","year":"2020","journal-title":"Angew. Chem."},{"issue":"1","key":"2026081806104976000_cit53","doi-asserted-by":"publisher","first-page":"1900996","DOI":"10.1002\/adhm.201900996","article-title":"Photodynamic Therapy\nCombined with Antihypoxic Signaling and CpG\nAdjuvant as an In Situ Tumor Vaccine Based on Metal\u2013Organic\nFramework Nanoparticles to Boost Cancer Immunotherapy","volume":"9","author":"Cai","year":"2020","journal-title":"Adv. Healthcare Mater."},{"key":"2026081806104976000_cit54","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3389\/fonc.2012.00119","article-title":"T lymphocytes and normal tissue responses to radiation","volume":"2","author":"Schaue","year":"2012","journal-title":"Front. Oncol."},{"issue":"10","key":"2026081806104976000_cit55","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells\nin the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat. Immunol."},{"issue":"4","key":"2026081806104976000_cit56","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.ijrobp.2011.09.049","article-title":"Maximizing tumor\nimmunity with fractionated radiation","volume":"83","author":"Schaue","year":"2012","journal-title":"Int. J.\nRadiat. Oncol., Biol., Phys."},{"key":"2026081806104976000_cit57","unstructured":"Lin, W.; He, C.; Lu, K.\n          Nanoparticles\nfor photodynamic therapy,\nX-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy,\nchemotherapy, immunotherapy, and any combination thereof. US\n201462063770 P."},{"issue":"5","key":"2026081806104976000_cit58","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/j.matt.2019.06.007","article-title":"Ultrathin Metal-Organic-Layer Mediated\nRadiotherapy-Radiodynamic Therapy","volume":"1","author":"Ni","year":"2019","journal-title":"Matter"},{"issue":"29","key":"2026081806104976000_cit59","doi-asserted-by":"publisher","first-page":"12579","DOI":"10.1021\/jacs.0c05039","article-title":"Nanoscale\nMetal\u2013Organic Framework Co-delivers TLR-7 Agonists and Anti-CD47\nAntibodies to Modulate Macrophages and Orchestrate Cancer Immunotherapy","volume":"142","author":"Ni","year":"2020","journal-title":"J. Am. Chem. Soc."},{"issue":"29","key":"2026081806104976000_cit60","doi-asserted-by":"publisher","first-page":"7641","DOI":"10.1039\/D0SC01949F","article-title":"Biomimetic nanoscale\nmetal\u2013organic framework harnesses hypoxia for effective cancer\nradiotherapy and immunotherapy","volume":"11","author":"Ni","year":"2020","journal-title":"Chem. Sci."},{"issue":"25","key":"2026081806104976000_cit61","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1056\/NEJM199706193362501","article-title":"Postmenopausal hormone therapy and mortality","volume":"336","author":"Grodstein","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"11\u201312","key":"2026081806104976000_cit62","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S0891-5849(99)00183-5","article-title":"DNA damage induced\nby catecholestrogens in the presence\nof copper (II): generation of reactive oxygen species and enhancement\nby NADH","volume":"27","author":"Thibodeau","year":"1999","journal-title":"Free Radical Biol. Med."}],"container-title":["Accounts of Chemical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.accounts.0c00313","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/achre4\/article-pdf\/53\/9\/1739\/12265201\/ar0c00313.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/achre4\/article-pdf\/53\/9\/1739\/12265201\/ar0c00313.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:24:21Z","timestamp":1787048661000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/achre4\/article\/53\/9\/1739\/1265938\/Nanoscale-Metal-Organic-Frameworks-for-Cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,18]]},"references-count":62,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,8,18]]},"published-print":{"date-parts":[[2020,9,15]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.accounts.0c00313","relation":{},"ISSN":["0001-4842","1520-4898"],"issn-type":[{"value":"0001-4842","type":"print"},{"value":"1520-4898","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,18]]}}}